Analysts at Paradigm Capital boosted their target price on shares of NordionInc(USA) (NYSE:NDZ) from $10.00 to $11.75 in a research report issued to clients and investors on Monday, American Banking and Market News reports. Paradigm Capital’s price objective points to a potential upside of 12.87% from the stock’s previous close. NordionInc (USA) (NYSE:NDZ) shares after opening at $11.55 moved to $11.62 on last trade day and at the end of the day closed at $11.52. Company price to sales ratio in past twelve months was calculated as 2.86 and price to cash ratio as 2.24. NordionInc (USA) (NYSE:NDZ)showed a positive weekly performance of 9.51%.
Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA) plunged about 12% after the U.S. Supreme Court decided to hear an appeal filed by Teva Pharmaceutical Industries Ltd (ADR) (NYSE:TEVA) in a patent fight over top-selling multiple sclerosis drug Copaxone, a move that could deter generic manufacturers from introducing cheaper versions onto the market as soon as May. Teva Pharmaceutical Industries Ltd (ADR) (NYSE:TEVA) shares after opening at $49.60 moved to $52.94 on last trade day and at the end of the day closed at $52.84. Company price to sales ratio in past twelve months was calculated as 2.45 and price to cash ratio as 47.96. Teva Pharmaceutical Industries Ltd (ADR) (NYSE:TEVA) showed a positive weekly performance of 7.55%.
Equities researchers at Citigroup Inc. lifted their target price on shares of Medtronic (NYSE:MDT) from $66.00 to $70.00 in a research report issued on Thursday, StockRatingsNetwork reports. Citigroup Inc.’s target price indicates a potential upside of 15.87% from the company’s current price. Medtronic, Inc. (NYSE:MDT) shares moved up 1.87% in last trading session and was closed at $61.54, while trading in range of $60.71 – 61.74. Medtronic, Inc. (NYSE:MDT) year to date (YTD) performance is 7.23%.
Leave a Reply